Traws Pharma, Inc. TRAW 深 沪
等待开盘 04-03 09:30:00 美东时间
1.64
-0.020
-1.20%
华盛通- 最 高1.72
- 今 开1.6725
- 成交量 8.59万股
- 最 低 1.49
- 昨 收 1.66
- 总市值 1310.50万
- 52周最高 3.265
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 0.97
- 委 比 85.43%
- 总股本 799.09万
- 历史最高 1751062.50
- 量 比 1.57
- 振 幅 13.86%
- 历史最低 0.97
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Traws Pharma Completed Clinical Analysis Of Its 90-patient, Open-label Phase 2 Study Of Ratutrelvir Versus Paxlovid For Mild-to-moderate Covid-19
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were
02-19 20:36
Traws Pharma Completes Enrollment In Ongoing 90-Patient, Open-Label Phase 2 Study Of Ratutrelvir, Investigational Oral, Ritonavir-Free Mpro/3CL Protease Inhibitor, Versus PAXLOVID, In COVID-19 Patients
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated
01-26 21:32
Traws Pharma shares are trading higher after the company announced the filing of a U.S. IND application with FDA for tivoxavir marboxil to treat influenza.
Traws Pharma shares are trading higher after the company announced the filing o...
01-14 03:01
Traws Pharma's Interim Data For Ratutrelvir Demonstrated A Differentiated Clinical Profile In Pre-specified Interim Analysis Of An Ongoing Open-label Phase 2 Study For Mild-to-moderate Covid-19, Final Data Analysis Expected In January 2026
The study was designed as an active-controlled comparator trial versus PAXLOVID™ (nirmatrelvir/ritonavir) and evaluated patient-reported symptom outcomes, safety, and real-world usability. A separate treatment arm
2025-12-17 19:02
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
HC Wainwright & Co. Initiates Coverage On Traws Pharma with Buy Rating, Announces Price Target of $8
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Traws Pharma (NASDAQ:TRAW) with a Buy rating and announces Price Target of $8.
2025-12-03 20:00
Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics
Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical stud...
2025-10-28 00:59
Traws Pharma Approves Executive Stock Options Grant
Traws Pharma ( ($TRAW) ) has provided an update. On October 12, 2025, Traws Pha...
2025-10-18 05:28
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Traws Pharma, Inc. has appointed John Leaman, MD, as an independent director, effective October 1, 2025. The company also removed the interim titles of its executives, Iain Dukes and Charles Parker, who are now CEO and CFO, respectively. Dr. Leaman brings extensive experience in finance and corporate strategy. The company is advancing ratutrelvir, a COVID-19 treatment, and tivoxavir marboxil, a potential bird flu and seasonal influenza therapy, w...
2025-10-06 11:00
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma announced the launch of Phase 2 trials for ratutrelvir, a ritonavir-free COVID treatment, to compare its safety and efficacy with Paxlovid. The trials will assess disease rebound rates, Long COVID incidence, and safety in Paxlovid-ineligible patients. Top-line results are expected by year-end 2025. Ratutrelvir aims to overcome shortcomings of current treatments, including unfavorable drug interactions and limited efficacy, with once-...
2025-08-18 11:00
